Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Since the market is focusing on the COVID vaccine performance and overlooking the revenue opportunity that Moderna's product candidates have, I believe long-term investors are likely to get rewarded.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

its only commercially available product until its RSV shot entered the market last year. It also comes ahead of Moderna's presentation at the annual JPMorgan Healthcare Conference, one of the largest ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product approvals over the next three years that could fuel growth. The conventional ...